The PFS hazard ratio ( HR ) ( selumetinib : placebo ) was @ -LSB- @ % confidence interval ( CI ) @-@ @ ; P = @ -RSB- , with a median PFS of @ months ( @ % CI @-@ @ ) for docetaxel plus selumetinib and @ months ( @ % CI @-@ @ ) for docetaxel alone .